A clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are initially developing for the treatment of patients with uncontrolled hypertension (uHTN), defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension (rHTN), defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Lead Underwriter
BofA Securities, Inc,
Co-Managers
Credit Suisse Securities (USA) LLC, Evercore Group L.L.C, Guggenheim Securities, LLC, Stifel Nicolaus & Company, Incorporated, Wells Fargo Securities, LLC
